SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                          Date of Report: July 7, 1999



                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)



                         Commission File Number: 0-19131




                 Delaware                          52-1555759
           (State of Incorporation)            (I.R.S. Employer
                                              Identification No.)



                35 West Watkins Mill Road, Gaithersburg, MD 20878
                (Address of principal executive office (Zip Code)


        Registrant's telephone number, including area code (301) 417-0770


                  No Exhibits are being filed with this report.


CytoGam and RespiGam are  registered  trademarks of the Company and Synagis is a
trademark.


MEDIMMUNE, INC.
Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune,  Inc.  reported  the  information  contained in the  following  press
release dated July 6, 1999:

FOR IMMEDIATE RELEASE

Contacts:
William C. Roberts                      Len Lavenda
Investor and Media Relations            Pasteur Merieux Connaught USA
MedImmune, Inc.                         570-839-4446
301-417-0770 x358


http://www.medimmune.com
http://www.us.pmc-vacc.com


MEDIMMUNE AND PASTEUR MERIEUX CONNAUGHT REPORT  PRESENTATION OF NEW DATA ON LYME
DISEASE VACCINE CANDIDATE AT INTERNATIONAL LYME MEETING

- Synergy between Decorin Binding Protein A and Outer Surface Protein A Shown in
Mouse Model -

Gaithersburg,  MD and Swiftwater,  PA, July 6, 1999 -- MedImmune,  Inc. (Nasdaq:
MEDI) and Pasteur Merieux Connaught,  a wholly owned subsidiary of Rhone-Poulenc
S.A.  (NYSE:  RP),  today  announced  the  presentation  of data  showing that a
combination  vaccine  composed  of  decorin  binding  protein A (DbpA) and outer
surface protein A (OspA) is more efficacious in preventing infection by Borrelia
burgdorferi and related species in mice than  vaccination  with either immunogen
alone.  B.burgdorferi is a bacterium which causes Lyme disease. The presentation
was given at the International Conference on Lyme Borreliosis and other Emerging
Tick-Borne Diseases in Munich,  Germany.  In these experiments,  the combination
vaccine  prevented   infection  in  mice  by  genetically   diverse  strains  of
B.burgdorferi.  These data  suggest that the addition of DbpA to an OspA vaccine
for Lyme disease might enhance the level of protection  provided by  vaccination
with OspA alone against infection by the Lyme disease-causing bacterium.

"Decorin  Binding  Protein has always shown promise as a second  generation Lyme
disease  vaccine  candidate  in that it  actively  targets  the  disease-causing
bacterium, B.burgdorferi, during the early stage of infection following the bite
of an infected tick," commented James Young, Ph.D.,  Executive Vice President of
Research and  Development  at MedImmune.  "This  apparent  synergy with OspA may
allow use of a combination vaccine with a broader efficacy than a single antigen
vaccine."

The study, authored by Mark Hanson, Ph.D. et al., entitled "Evidence for Vaccine
Synergy Between Borrelia  burgdorferi Decorin Binding Protein A (DbpA) and Outer
Surface  Protein A (OspA) in the Mouse Model of Lyme  Borreliosis,"  showed that
the  mechanisms of  immunoprophylaxis  provided by DbpA and OspA may  complement
each other when compared to  immunoprophylaxis  with either antigen  alone.  The
scientists  compared  the  efficacy  of the  combination  vaccine  to the single
antigen  vaccines in preventing  infection after  escalating  challenge doses of
B.burgdorferi. The combination vaccine was shown to completely prevent infection
at all challenge doses. Additionally,  very low doses of the combination vaccine
were more effective than higher doses of the single antigen  vaccines.  Finally,
the combination  vaccine was shown to be more effective in preventing  infection
after challenge with heterologous  strains of B.burgdorferi,  compared to either
single antigen vaccine.

"These  experimental data are particularly  exciting as the combination  vaccine
demonstrates its ability to prevent infection with heterologous strains commonly
found outside the U.S.," added Alf Lindberg,  Senior Vice  President of Research
and Development at Pasteur Merieux Connaught.  "This combination vaccine has the
potential to provide  protection  against strains found throughout the world and
may provide the basis for an improved and international Lyme vaccine."

DbpA  was  discovered  by  Magnus  Hook,  Ph.D.  and  Betty  Guo  at  Texas  A&M
University's  Institute of  Biosciences  and  Technology  in Houston,  Texas and
exclusively  licensed  to  MedImmune.  These  scientists  found  that a  protein
expressed by spirochetes which cause Lyme disease,  including  B.burgdorferi and
related  species,  could bind to a protein  called  "decorin"  commonly found in
human skin and  connective  tissue.  Hook and Guo  determined  the gene sequence
encoding the protein in 1995. Both groups found that animals immunized with DbpA
can be protected from challenge with the bacterium.  These researchers have also
shown the  ability of  antibodies  directed  against  DbpA to inhibit  growth of
B.burgdorferi  and  related  strains,   including   isolates  not  inhibited  by
antibodies directed against OspA.

Lyme disease is the most common  arthropod-borne  disease in the United  States.
Forty-eight  states have reported cases of Lyme disease,  with a reported annual
incidence of  approximately  16,000 new cases  nationwide.  Lyme disease is also
reported  in  Europe,  Japan,  China  and  Russia.  The  disease  is caused by a
bacterium  known as B.  burgdorferi  and  related  species,  and is  transferred
through  a  tick,  primarily  Ixodes  scapularis,  most  commonly  found  on the
white-footed  mouse or deer in the  northeastern  U.S.  When the tick feeds on a
human  host,  it can  transmit  bacteria to the host,  thereby  beginning a Lyme
disease infection.

Following a tick bite,  an infected  person will often  develop a circular  rash
with a bulls-eye  pattern.  Weeks to months later,  this rash may be followed by
neurological,  cardiac and joint  abnormalities,  malaise  and general  flu-like
symptoms. Early treatment with antibiotics is generally most effective; however,
some infections,  particularly if diagnosed late, have proven to be resistant to
antibiotic therapy.  Difficulties with early diagnosis as well as the occurrence
of  serious  treatment-resistant  infections  emphasize  the  need  for safe and
effective vaccines against Lyme disease.

In December 1998, MedImmune and Pasteur Merieux Connaught entered into a license
agreement  to develop a second  generation  vaccine for the  prevention  of Lyme
disease.  The first generation  vaccine candidate of Pasteur Merieux  Connaught,
based  on outer  surface  protein  A found on the  organism  which  causes  Lyme
disease, has completed a Phase 3 clinical trial.  Pursuant to its agreement with
MedImmune,  Pasteur  Merieux  Connaught  gained  exclusive  worldwide  rights to
MedImmune's  technology  related to decorin binding  protein,  also found on the
organism which causes Lyme disease.  Pasteur  Merieux  Connaught  intends to use
DbpA for the  development of European and possibly  improved U.S.,  vaccines for
the prevention of Lyme disease.

MedImmune, a biotechnology company located in Gaithersburg, Maryland, is focused
on developing and marketing products that address medical needs in areas such as
infectious disease,  transplantation medicine,  autoimmune disorders and cancer.
The Company  currently  markets  Synagis  (palivizumab),  RespiGam  (Respiratory
Syncytial   Virus   Immune   Globulin   Intravenous   (Human)),    and   CytoGam
(Cytomegalovirus Immune Globulin Intravenous (Human)) through its hospital-based
sales force and has five new product candidates in clinical trials.

Pasteur Merieux Connaught  (Rhone-Poulenc  Group) is the world's largest vaccine
company with the broadest range of products.  The company produces more than one
billion doses of vaccines every year to immunize 400 million people worldwide.

Rhone-Poulenc S.A.,  headquartered in Paris,  France, is a leading life sciences
company,  growing  through  innovations  in human,  plant and animal  health and
through its specialty chemicals subsidiary,  Rhodia. With sales in 1998 of $14.7
billion, the company employs 65,000 people in 160 countries worldwide.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a number  of  factors,  including  risks  and  uncertainties  discussed  in both
companies' filings with the U.S. Securities and Exchange Commission.

                                      ####


(REGISTRANT)      MEDIMMUNE, INC.




BY (SIGNATURE)    /s/ David M. Mott
(NAME AND TITLE)  David M. Mott, Vice Chairman and Chief Financial Officer
(DATE)            July 6, 1999
[{"type": "8-K", "sequence": "1", "description": "MEDIMMUNE AND PASTEUR MERIEUX CONNAUGHT REPORT", "secsgml_size_bytes": 9511}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14657", "film-number": "99659886"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                          Date of Report: July 7, 1999

                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)

                         Commission File Number: 0-19131

                 Delaware                          52-1555759
           (State of Incorporation)            (I.R.S. Employer
                                              Identification No.)

                35 West Watkins Mill Road, Gaithersburg, MD 20878
                (Address of principal executive office (Zip Code)

        Registrant's telephone number, including area code (301) 417-0770

                  No Exhibits are being filed with this report.

CytoGam and RespiGam are  registered  trademarks of the Company and Synagis is a
trademark.

MEDIMMUNE, INC.
Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune,  Inc.  reported  the  information  contained in the  following  press
release dated July 6, 1999:

FOR IMMEDIATE RELEASE

Contacts:
William C. Roberts                      Len Lavenda
Investor and Media Relations            Pasteur Merieux Connaught USA
MedImmune, Inc.                         570-839-4446
301-417-0770 x358

http://www.medimmune.com
http://www.us.pmc-vacc.com

MEDIMMUNE AND PASTEUR MERIEUX CONNAUGHT REPORT  PRESENTATION OF NEW DATA ON LYME
DISEASE VACCINE CANDIDATE AT INTERNATIONAL LYME MEETING

- Synergy between Decorin Binding Protein A and Outer Surface Protein A Shown in
Mouse Model -

Gaithersburg,  MD and Swiftwater,  PA, July 6, 1999 -- MedImmune,  Inc. (Nasdaq:
MEDI) and Pasteur Merieux Connaught,  a wholly owned subsidiary of Rhone-Poulenc
S.A.  (NYSE:  RP),  today  announced  the  presentation  of data  showing that a
combination  vaccine  composed  of  decorin  binding  protein A (DbpA) and outer
surface protein A (OspA) is more efficacious in preventing infection by Borrelia
burgdorferi and related species in mice than  vaccination  with either immunogen
alone.  B.burgdorferi is a bacterium which causes Lyme disease. The presentation
was given at the International Conference on Lyme Borreliosis and other Emerging
Tick-Borne Diseases in Munich,  Germany.  In these experiments,  the combination
vaccine  prevented   infection  in  mice  by  genetically   diverse  strains  of
B.burgdorferi.  These data  suggest that the addition of DbpA to an OspA vaccine
for Lyme disease might enhance the level of protection  provided by  vaccination
with OspA alone against infection by the Lyme disease-causing bacterium.

"Decorin  Binding  Protein has always shown promise as a second  generation Lyme
disease  vaccine  candidate  in that it  actively  targets  the  disease-causing
bacterium, B.burgdorferi, during the early stage of infection following the bite
of an infected tick," commented James Young, Ph.D.,  Executive Vice President of
Research and  Development  at MedImmune.  "This  apparent  synergy with OspA may
allow use of a combination vaccine with a broader efficacy than a single antigen
vaccine."

The study, authored by Mark Hanson, Ph.D. et al., entitled "Evidence for Vaccine
Synergy Between Borrelia  burgdorferi Decorin Binding Protein A (DbpA) and Outer
Surface  Protein A (OspA) in the Mouse Model of Lyme  Borreliosis,"  showed that
the  mechanisms of  immunoprophylaxis  provided by DbpA and OspA may  complement
each other when compared to  immunoprophylaxis  with either antigen  alone.  The
scientists  compared  the  efficacy  of the  combination  vaccine  to the single
antigen  vaccines in preventing  infection after  escalating  challenge doses of
B.burgdorferi. The combination vaccine was shown to completely prevent infection
at all challenge doses. Additionally,  very low doses of the combination vaccine
were more effective than higher doses of the single antigen  vaccines.  Finally,
the combination  vaccine was shown to be more effective in preventing  infection
after challenge with heterologous  strains of B.burgdorferi,  compared to either
single antigen vaccine.

"These  experimental data are particularly  exciting as the combination  vaccine
demonstrates its ability to prevent infection with heterologous strains commonly
found outside the U.S.," added Alf Lindberg,  Senior Vice  President of Research
and Development at Pasteur Merieux Connaught.  "This combination vaccine has the
potential to provide  protection  against strains found throughout the world and
may provide the basis for an improved and international Lyme vaccine."

DbpA  was  discovered  by  Magnus  Hook,  Ph.D.  and  Betty  Guo  at  Texas  A&M
University's  Institute of  Biosciences  and  Technology  in Houston,  Texas and
exclusively  licensed  to  MedImmune.  These  scientists  found  that a  protein
expressed by spirochetes which cause Lyme disease,  including  B.burgdorferi and
related  species,  could bind to a protein  called  "decorin"  commonly found in
human skin and  connective  tissue.  Hook and Guo  determined  the gene sequence
encoding the protein in 1995. Both groups found that animals immunized with DbpA
can be protected from challenge with the bacterium.  These researchers have also
shown the  ability of  antibodies  directed  against  DbpA to inhibit  growth of
B.burgdorferi  and  related  strains,   including   isolates  not  inhibited  by
antibodies directed against OspA.

Lyme disease is the most common  arthropod-borne  disease in the United  States.
Forty-eight  states have reported cases of Lyme disease,  with a reported annual
incidence of  approximately  16,000 new cases  nationwide.  Lyme disease is also
reported  in  Europe,  Japan,  China  and  Russia.  The  disease  is caused by a
bacterium  known as B.  burgdorferi  and  related  species,  and is  transferred
through  a  tick,  primarily  Ixodes  scapularis,  most  commonly  found  on the
white-footed  mouse or deer in the  northeastern  U.S.  When the tick feeds on a
human  host,  it can  transmit  bacteria to the host,  thereby  beginning a Lyme
disease infection.

Following a tick bite,  an infected  person will often  develop a circular  rash
with a bulls-eye  pattern.  Weeks to months later,  this rash may be followed by
neurological,  cardiac and joint  abnormalities,  malaise  and general  flu-like
symptoms. Early treatment with antibiotics is generally most effective; however,
some infections,  particularly if diagnosed late, have proven to be resistant to
antibiotic therapy.  Difficulties with early diagnosis as well as the occurrence
of  serious  treatment-resistant  infections  emphasize  the  need  for safe and
effective vaccines against Lyme disease.

In December 1998, MedImmune and Pasteur Merieux Connaught entered into a license
agreement  to develop a second  generation  vaccine for the  prevention  of Lyme
disease.  The first generation  vaccine candidate of Pasteur Merieux  Connaught,
based  on outer  surface  protein  A found on the  organism  which  causes  Lyme
disease, has completed a Phase 3 clinical trial.  Pursuant to its agreement with
MedImmune,  Pasteur  Merieux  Connaught  gained  exclusive  worldwide  rights to
MedImmune's  technology  related to decorin binding  protein,  also found on the
organism which causes Lyme disease.  Pasteur  Merieux  Connaught  intends to use
DbpA for the  development of European and possibly  improved U.S.,  vaccines for
the prevention of Lyme disease.

MedImmune, a biotechnology company located in Gaithersburg, Maryland, is focused
on developing and marketing products that address medical needs in areas such as
infectious disease,  transplantation medicine,  autoimmune disorders and cancer.
The Company  currently  markets  Synagis  (palivizumab),  RespiGam  (Respiratory
Syncytial   Virus   Immune   Globulin   Intravenous   (Human)),    and   CytoGam
(Cytomegalovirus Immune Globulin Intravenous (Human)) through its hospital-based
sales force and has five new product candidates in clinical trials.

Pasteur Merieux Connaught  (Rhone-Poulenc  Group) is the world's largest vaccine
company with the broadest range of products.  The company produces more than one
billion doses of vaccines every year to immunize 400 million people worldwide.

Rhone-Poulenc S.A.,  headquartered in Paris,  France, is a leading life sciences
company,  growing  through  innovations  in human,  plant and animal  health and
through its specialty chemicals subsidiary,  Rhodia. With sales in 1998 of $14.7
billion, the company employs 65,000 people in 160 countries worldwide.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a number  of  factors,  including  risks  and  uncertainties  discussed  in both
companies' filings with the U.S. Securities and Exchange Commission.

                                      ####

(REGISTRANT)      MEDIMMUNE, INC.

BY (SIGNATURE)    /s/ David M. Mott
(NAME AND TITLE)  David M. Mott, Vice Chairman and Chief Financial Officer
(DATE)            July 6, 1999